Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

Neurology

Volumn 60, Issue 1, 2003, Pages 69-73

  Nutt, J G ^a   Burchiel, K J ^a   Comella, C L ^a   Jankovic, J ^a   Lang, A E ^a   Laws Jr , E R ^a   Lozano, A M ^a   Penn, R D ^a   Simpson Jr , R K ^a   Stacy, M ^a   Wooten, G F ^a   Johnston, L ^a   Lopez, J ^a   Harrigan, M ^a   Marciano, F F ^a   Carter, J H ^a   Stone, C ^a   Trugman, J ^a   Rost Ruffner, E ^a   O'Brien, C ^a   McVicker, J H ^a   Davis, T L ^a   Charles, D ^a   Allen, G ^a   Weiner, W ^a   Landy, H J ^a   Bronstein, J ^a   Koller, W ^a   Pahwa, R ^a   Wilkinson, S ^a   Siemers, E R ^a   Wojcieszek, J M ^a   Witt, T ^a   Tuite, P J ^a   Ebbitt, B J ^a   Maxwell, R ^a   Cravets, M ^a   Hilt, D ^a   Klein, M ^a   Lee D R , ^a   Schultz B , ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; AKINESIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIPLOPIA; DOPAMINERGIC NERVE CELL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; DYSTONIA; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPESTHESIA; HYPONATREMIA; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARESTHESIA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; RASH; SUBSTANTIA NIGRA; TASTE DISORDER; THORAX PAIN; TINNITUS; TREMOR; VERTIGO; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

EID: 0037435511     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.60.1.69     Document Type: Article

References (17)

1. Gash DM, Zhang Z, Gerhardt GA. Neuroprotective and neurorestortative properties of GDNF. Ann Neurol 1998;44(suppl 1):S121-S125.
2. Bjorklund A, Rosenblad C, Winkler C. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997;4:186-200.
3. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380:252-255.
4. Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997;282:1396-1401.
5. Hoehn MM, Yahr MD. Parkinsonism. Onset, progression and mortality. Neurology 1967;17:427-442.
6. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease. London: Macmillan, 1987;153-163.
7. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
8. Kordower JH, Palfi S, Chen E-Y, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-424.
9. Ovadia A, Zhang Z, Gash DM. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging 1995;16:931-937.
10. Pelleymounter MA, Cullen MJ, Willman CL. Characteristics of BDNF-induced weight loss in rats. Exp Neurol 1995;131:229-238.
11. Eriksdotter JM, Norberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dementia Geriatr Cog Disord 1998;9:246-257.
12. Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994;36:244-246.
13. Bennett DLH. Neurotrophic factors: important regulators of nociceptive function. Neuroscientist 2001;7:13-17.
14. Ramer MS, Priestley JV, McMahon B. Functional regeneration of sensory axons into the adult spinal cord. Nature 2000;403:312-316.
15. Hoane MR, Gulwadi AG, Morrison S, et al. Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Exp Neurol 1999;160:235-243.
16. Gill SS, Patel NK, O'Sullivan K, et al. Intra-parenchymal putaminal administration of glial-derived neurotrophic factor in the treatment of advanced Parkinson's disease. Neurology 2002;58(suppl 3):A241. Abstract.
17. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-773.